Showing results (1-10 of 120) with videos related to

Sort By:
Pageof 12
Oncology (Williston Park, N.Y.)|October 17, 2002
Practitioners' practical model for managing cancer-related anemiaRobert E Smith, Simon Tchekmedyian
Clinical Drug Investigation|December 14, 2006
Resource utilisation and time commitment associated with correction of anaemia in cancer patients using epoetin alfaKenneth R Meehan, N Simon Tchekmedyian, Robert E Smith, et al.
Oncology (Williston Park, N.Y.)|October 17, 2002
Anemia in cancer patients: significance, epidemiology, and current therapyN Simon Tchekmedyian
Supportive Cancer Therapy|July 17, 2008
Hemoglobin increase is associated with improved health-related quality of life in patients with cancer not receiving chemotherapyJr Robert E Smith, John A Glaspy, N Simon Tchekmedyian, et al.
Oncology (Williston Park, N.Y.)|November 19, 2002
Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapyJohn A Glaspy, N Simon Tchekmedyian
Cancer Investigation|July 2, 2010
Disease progression increases the risk of skeletal-related events in patients with bone metastases from castration-resistant prostate cancer, lung cancer, or other solid tumorsN Simon Tchekmedyian, Yin-Miao Chen, Fred Saad
Cancer|July 2, 2003
The relationship between psychologic distress and cancer-related fatigueN Simon Tchekmedyian, Joel Kallich, Anne McDermott, et al.
Clinical Lung Cancer|November 24, 2004
Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complicationsVera Hirsh, N Simon Tchekmedyian, Lee S Rosen, et al.
The Oncologist|February 14, 2007
Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapyDavid H Henry, Naomi V Dahl, Michael Auerbach, et al.
The Journal of Urology|May 29, 2003
Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancerMatthew R Smith, James Eastham, Donald M Gleason, et al.
Pageof 12